Perscitus LLP
Private equityLondon · Pre-Seed–Late Stage · 10 people tracked
Investment thesis
Perscitus consults on a multi-asset portfolio emphasizing private equity, pursuing an opportunistic direct-investment strategy that stays flexible on sector, deal size, ownership stake (minority or majority) and holding period. It typically targets UK-headquartered companies exhibiting at least two of the following: strong IP, high growth, or a credible path to breakeven or a value-inflection milestone. Direct investments span four areas: venture capital (generally pre-Series A, with no EIS requirement and openness to special situations, secondaries and CLNs); life sciences focused on therapeutics addressing large unmet needs, preferably IND-ready or post-Phase 1; small UK buyouts/buy-ins of profitable companies with £5-£30m enterprise value; and selective sponsor-led co-investments.
Source: firm website, verified Aug 2, 2026.
Team · 10 people
from the firm's websiteJoined Perscitus in 2015; previously led technology deal teams for family office investors and worked at Truffle Capital and 3i's Growth Capital team. Began his career as an engineer, including work on the EU hydrogen fuel cell bus program. Holds an engineering degree from McGill, a Masters of Applied Science from UBC, and an MBA from EM Lyon.
Joined the team in 2007 focusing on private client tax, advising on offshore, residence, domicile and inheritance tax. Previously a Chartered Tax Adviser at BDO and PwC. Holds a law degree from Warwick University.
Joined Perscitus in 2016 after working in the private equity team at Signia Wealth from 2013. Holds a BSc in Economic History from LSE and interned at Goldman Sachs.
Manages the portfolio of clinical trials funded by the Jon Moulton Charity Trust. Previously Quality Manager at King's Health Partners Clinical Trials Office. Holds a BSc from Salford University and a PhD in Molecular Pharmacology from the University of Leeds, with over 25 years in clinical research.
Joined Perscitus in 2019 after seven years in the Ventures team at Downing LLP, where he led transactions and held board seats. A Chartered Accountant trained at PwC in London and Hong Kong.
Joined Perscitus in November 2018 after roles at Marble Bar Asset Management and Parus Finance. Holds the IMC and a BA Hons from the University of Leeds.
Joined Perscitus in 2022 as PA to the investor team. Previously spent much of her career at leadership advisory firm Egon Zehnder supporting executives.
Has worked with Jon Moulton since 1985 at Schroder Ventures and Alchemy Partners. Joined the family office in 2000 and serves as a consultant to the partnership.
Joined Perscitus in 2014 after working in the private equity advisory program at multi-family office Signia Wealth and in corporate broking at Seymour Pierce and Astaire Securities. Holds a BA from Kings College London and an MA from Regents Business School.
Solicitor and General Counsel at Perscitus, joining in 2018 after a year at Better Capital. Previously General Counsel at Equistone and Alchemy and past Chair of the BVCA's Legal and Technical Committee.
Principals & officers · per Companies House
what is this? ⓘLLP designated member · since 2016
LLP designated member · since 2019
LLP designated member · since 2024
Frequently asked questions
- What stage does Perscitus LLP invest at?
- Perscitus LLP invests at the Pre-Seed, Seed, Growth, Late Stage stages.
- What sectors does Perscitus LLP focus on?
- Perscitus LLP focuses on Biotech, Sector Agnostic.
- Where is Perscitus LLP located?
- Perscitus LLP is headquartered in London, GB.
Similar investors
8VC is a venture capital firm built on its 'Smart Enterprise' thesis, investing in data integration platforms and network-effect businesses across multiple industries.
B Capital Group is a multistage venture capital firm that invests from seed to late stage, offering value-added support to founders in partnership with management consulting firm BCG.
DCVC (Data Collective) is a deep tech venture capital firm backing entrepreneurs using computational approaches to solve large real-world problems across many industries. It operates six flagship funds plus DCVC Bio, spanning 13 funds to date.
General Catalyst is a venture capital firm operating as a partnership that engages in company building across sectors and stages, backing businesses to accelerate their trajectory.
Inveready is a Spanish alternative investment firm founded in 2008 as a venture fund, now active across the small and mid-market segment. It manages dedicated funds spanning venture capital, life sciences, venture debt, public markets (PIPE), private equity and infrastructure, alongside wealth management services.